No previous suggestions found.

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

1
Home
Companies

Vaxcyte

#1522

Rank

$11.6B

Marketcap

US United States

Country

Vaxcyte
Leadership team

Mr. Grant E. Pickering M.B.A. (Co-Founder, CEO & Director)

Mr. Andrew L. Guggenhime M.B.A. (Pres, CFO & Principal Accounting Officer)

Mr. James Wassil M.B.A., M.S. (Exec. VP & COO)

Products/ Services
Biopharma, Biotechnology, Health Care
Number of Employees
50 - 100
Headquarters
San Carlos, California, United States
Established
2013
Company Registration
SEC CIK number: 0001649094
Traded as
PCVX
Social Media
URL
https://vaxcyte.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
History

Vaxcyte was founded in 2018, combining the pioneering spirit of innovation, unyielding commitment to science, and drive to help prevent, control and manage life-threatening infectious diseases.

Mission
To develop and deliver vaccines, treatments and cures that benefit humankind worldwide.
Vision
Vaxcyte’s vision is to be a world leader in the prevention, control and management of life-threatening infectious diseases.
Key Team

Mr. Paul W. Sauer M.B.A., MBA (Sr. VP of Process Devel. & Manufacturing)

Mr. Harp Dhaliwal M.B.A. (Sr. VP of Commercial Manufacturing & Supply Chain)

Dr. Ashish Khanna M.B.A., Ph.D. (Co-Founder and Chief Bus. Officer)

Dr. Jeff Fairman Ph.D. (Co-Founder & VP of Research)

Ms. Janet Graesser (VP of Corp. Communications & Investor Relations)

Mr. Mikhail Eydelman J.D. (Sr. VP, Gen. Counsel & Corp. Sec.)

Karen Alderete (Exec. Director of HR)

Recognition and Awards
Vaxcyte has received a number of awards and recognition, including the 2019 Top-10 Emerging US Biotechnology Company, 2020 Top-10 Most Innovative Biotechnology Company, and 2021 Top-10 Breakthrough Vaccine Company.
References

https://in.investing.com/equities/vaxcyte-inc

https://finance.yahoo.com/quote/PCVX/profile?p=PCVX

https://www.crunchbase.com/organization/sutrovax

https://sec.report/CIK/0001649094

https://companiesmarketcap.com/

https://vaxcyte.com

Vaxcyte
Leadership team

Mr. Grant E. Pickering M.B.A. (Co-Founder, CEO & Director)

Mr. Andrew L. Guggenhime M.B.A. (Pres, CFO & Principal Accounting Officer)

Mr. James Wassil M.B.A., M.S. (Exec. VP & COO)

Products/ Services
Biopharma, Biotechnology, Health Care
Number of Employees
50 - 100
Headquarters
San Carlos, California, United States
Established
2013
Company Registration
SEC CIK number: 0001649094
Traded as
PCVX
Social Media
URL
https://vaxcyte.com
About

Businessabc provides digital business directory, digital blockchain AI certification, resources, and marketplace for businesses, organisations, and professionals.

Contacts

businessabc@ztudium.com

Follow Us
Produced by
In collaboration with
Logo

Copyright 2024 © Businessabc powered by ztudium

Privacy Policy